Moleculin Biotech, Inc. (MBRX)

$4.61

+0.18

(+3.95%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $4.45
    $4.70
    $4.61
    downward going graph

    3.47%

    Downside

    Day's Volatility :5.32%

    Upside

    1.91%

    downward going graph
  • $3.22
    $15.75
    $4.61
    downward going graph

    30.15%

    Downside

    52 Weeks Volatility :79.56%

    Upside

    70.73%

    downward going graph

Returns

PeriodMoleculin Biotech, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-0.86%
5.9%
0.0%
6 Months
-43.8%
5.5%
0.0%
1 Year
-53.66%
10.9%
0.0%
3 Years
-90.46%
15.6%
-17.0%

Highlights

Market Capitalization
10.3M
Book Value
$9.34
Earnings Per Share (EPS)
-13.04
PEG Ratio
0.0
Wall Street Target Price
35.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-42.66%
Return On Equity TTM
-79.75%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-27.8M
Diluted Eps TTM
-13.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.15
EPS Estimate Next Year
-5.6
EPS Estimate Current Quarter
-3.53
EPS Estimate Next Quarter
-3.22

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Moleculin Biotech, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 659.22%

Current $4.61
Target $35.00

Technicals Summary

Sell

Neutral

Buy

Moleculin Biotech, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
21.96%
-43.8%
-53.66%
-90.46%
-95.66%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
NA
NA
0.0
-8.15
-0.8
-0.43
NA
9.34
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
Buy
$10.3M
-95.66%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Moleculin Biotech, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 62.3% return, outperforming this stock by 116.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 284.8%

Institutional Holdings

  • Armistice Capital, LLC

    6.42%
  • Vanguard Group Inc

    3.26%
  • Geode Capital Management, LLC

    0.72%
  • BlackRock Inc

    0.54%
  • ATTICUS WEALTH MANAGEMENT, LLC

    0.14%
  • Newbridge Financial Services Group, Inc.

    0.03%

Company Information

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.

Organization
Moleculin Biotech, Inc.
Employees
18
CEO
Mr. Walter V. Klemp
Industry
Health Technology

FAQs